Drug Discovery Re-Invented; Emerging Role of Biotechs, Academics and Non-Profits (DDRI)
Venue: Hilton Scottsdale Resort & Villas
Location: Scottsdale, Arizona, United States
Event Date/Time: Oct 16, 2013 / 10:00 am - (MST) | End Date/Time: Oct 19, 2013 / 1:30 pm - (MST) |
Registration Date: Aug 21, 2013 | Time: 12:00:00 - (MST) |
Early Registration Date: May 01, 2013 | Time: 12:00:00 - (MST) |
Abstract Submission Date: May 20, 2013 | Time: 12:00:00 - (MST) |
Description
Registration Deadline: 21st August 2013
The full programme is now available, please see conference website for details. The conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.
Key Sessions include:
- Discovery Re-Invented
- Novel Pharma Approaches
- Collaborative Drug Discovery
- Natural Products
- Structure, Modelling and Informatics
- Biologics and Non-traditional Therapeutics
- Discovery Technologies
- Exclusive Exhibit (please contact us for booth pricing, limited availability)
This conference is designed to attract the following attendees: medicinal, computational, and synthetic organic chemists; structural and screening biologists; research management and entrepreneurs; industrial and academic scientists.
Confirmed Speakers
Prof. William Jorgensen (Plenary) ,Yale University
Prof. Jef De Brabander, UT Southwestern Medical
Dr. Bart DeCorte, Janssen Research & Development
Prof. James Barrow, Johns Hopkins School of Medicine
Dr. Ken Duncan (Plenary), Bill & Melinda Gates Foundation
Dr. Guy Breitenbucher, Dart Neuroscience
Dr. Barry Bunin, Collaborative Drug Discovery
Dr. Paul Labute, Chemical Computing Group
Dr. Leah Frye, Schrödinger
Prof. Sean Brady, The Rockefeller University
Dr. Steven Young (Plenary) BeiGene
Dr. Craig Thomas, NIH Chemical Genomics Center
Dr. Michael Trzoss, Trius Therapeutics
Dr. Joseph Vacca, WuXi AppTec
Dr. Michael Goetz, Natural Products Discovery Institute
Prof. George Georgiou (Plenary), The University of Texas at Austin
Dr. Benjamin Blass, Temple University School of Pharmacy
Prof. Kenneth Merz, University of Florida
Dr. Michael Foley (Plenary), Broad Institute
Dr. David Gorenstein, University of Texas HSC Houston
Dr. Zhengying Pan, Peking University, Shenzhen Graduate School
Dr. Andreas G. Bader, Mirna Therapeutics
Dr. Todd Chappell, NIH and BioHealth Innovation
Dr. Trevor Hallam, Sutro Biopharma
Dr. Patrick Lam, Lam Drug Discovery Consulting
Dr. Sandhya Kortagere, Drexel University College of Medicine
Dr. Mark McDonnell, Fox Chase Chemical Diversity Center
Dr. Serge L Boulet, Eli Lilly
Dr. Gabor Butora, Merck
Dr. Janet L. Ralbovsky, University of Tennessee Research Foundation
Dr Paul Leeson, GlaxoSmithKline
Dr Matthew Segall, Optibrium Ltd.
Dr. Guy Carter, Biosortia Pharmaceuticals
Dr Chris Williams, Chemical Computing Group
Dr. Phil Cox, Noramco
Dr. David Lowe, Æglea BioTherapeutics
Dr. Kristopher Josephson, Ra Pharmaceuticals
Dr. Erin Duffy, Rib-X
Dr. Joel Dudley, Mount Sinai School of Medicine
Venue
Additional Information
Registration Deadline: 21st August 2013
The full programme is now available, please see conference website for details.
Exclusive Exhibit (please contact us for booth pricing, limited availability)